Sandbox carlos: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 11: Line 11:
:::* Preferred regimen:[[Macrolides]] ([[azithromycin]], [[clarithromycin]], {{or}} [[erythromycin]]) (strong recommendation) level I evidence  
:::* Preferred regimen:[[Macrolides]] ([[azithromycin]], [[clarithromycin]], {{or}} [[erythromycin]]) (strong recommendation) level I evidence  
:::* Alternative regimen: [[Doxycycline]]
:::* Alternative regimen: [[Doxycycline]]
:::2.2 '''Preferred regimen in presence of comorbidities, such as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs; use of antimicrobials within the previous 3 months or other risks for drug resistant Streptococcus pneumoniae infection:''' Option A [[Fluoroquinolone]] ([[moxifloxacin]], [[gemifloxacin]], {{or}} [[levofloxacin]] Option B [[β-lactam]] {{PLUS}} a [[macrolide]]  
:::2.2 Preferred regimen in presence of comorbidities, such as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs; use of antimicrobials within the previous 3 months or other risks for drug resistant Streptococcus pneumoniae infection: Option A [[Fluoroquinolone]] ([[moxifloxacin]], [[gemifloxacin]], {{or}} [[levofloxacin]] Option B [[β-lactam]] {{PLUS}} a [[macrolide]]  


::* 3. '''Inpatient non Intensive care unit treatment'''
::* 3. '''Inpatient non Intensive care unit treatment'''

Revision as of 13:53, 15 July 2015

  • 1. Community-acquired pneumonia


  • 2. Outpatient treatment
  • 2.1 Previously healthy and no risk factors for drug-resistant Streptococcus pneumoniae infection:
2.2 Preferred regimen in presence of comorbidities, such as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs; use of antimicrobials within the previous 3 months or other risks for drug resistant Streptococcus pneumoniae infection: Option A Fluoroquinolone (moxifloxacin, gemifloxacin, OR levofloxacin Option B β-lactam Template:PLUS a macrolide
  • 3. Inpatient non Intensive care unit treatment
  • Preferred regimen:fluoroquinolone
  • Preferred regimen in presence of comorbidities, such as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs; use of antimicrobials within the previous 3 months or other risks for drug resistant Streptococcus pneumoniae infection: Option A Fluoroquinolone (moxifloxacin, gemifloxacin, OR levofloxacin Option B β-lactam Template:PLUS a macrolide


References

  1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC; et al. (2007). "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults". Clin Infect Dis. 44 Suppl 2: S27–72. doi:10.1086/511159. PMID 17278083.
  2. Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.